HYDERABAD: A day after Serum Institute of India (SII)’s CEO Adar Poonawalla announced a Rs 100 per dose cut in Covishield prices for state governments, indigenous Covid-19 vaccine developer Bharat Biotech followed suit, albeit with a price reduction of Rs 200 per dose for Covaxin.
On Thursday, Bharat Biotech announced that is is slashing Covaxin prices from the earlier announced Rs 600 per dose to Rs 400 per dose for state governments.
“Bharat Biotech is deeply concerned with the critical pandemic circumstances that India is facing at this time. Recognising the enormous challenges to the public health care system, we have made Covaxin available to state governments at a price of Rs 400 per dose,” Bharat Biotech said in its announcement.
“We wish to be transparent in our approach to pricing which was determined by internally funded product development, several operational-intensive BSL-3 manufacturing facilities (the first of its kind in the country) and clinical trials,” it said.
“We wish to champion ‘Innovation in India’ and our commitment to public health is absolute,” Bharat Biotech added.
On Wednesday, SII’s Adar Poonawalla had tweeted the price reduction terming it as a “philanthropic gesture” amid a public backlash and concerns over profiteering at a time that the pandemic is ravaging the country.
“As a philanthropic gesture, I hereby reduce the price to the states from Rs 400 to Rs 300 per dose, effective immediately; this will save thousands of crores of state funds going forward. This will enable more vaccinations and save countless lives,” Poonawalla had tweeted.